As­traZeneca's Farx­i­ga gets rough FDA re­view date for ground­break­ing move in­to chron­ic kid­ney dis­ease

As­traZeneca’s Farx­i­ga broke ground last year with an FDA nod for heart fail­ure pa­tients with or with­out type 2 di­a­betes — a first-in-class ap­proval. But Farx­i­ga isn’t done in­no­vat­ing and is now look­ing at a ap­proval in the com­ing months in an­oth­er po­ten­tial block­buster in­di­ca­tion.

The FDA will re­view As­traZeneca’s ap­pli­ca­tion to take SGLT2 in­hibitor Farx­i­ga in­to chron­ic kid­ney dis­ease some­time in the sec­ond quar­ter af­ter tag­ging the drug for pri­or­i­ty re­view, the British drug­mak­er said Wednes­day. CKD is be­lieved to cur­rent­ly af­fect rough­ly 37 mil­lion US pa­tients, As­traZeneca said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.